Ichnos Glenmark Innovation’s Post

Our BEAT® platform enables deep exploration of the bi/multispecific design space to optimize drug candidates and unlock new biology including T-cell, NK cells, and macrophage engagers. We leveraged this proprietary technology to create both of our clinical-stage assets being studied in multiple myeloma. Interested in learning more about collaborating with IGI within oncology, autoimmune diseases or beyond? Check out https://bit.ly/3SzfLiG. #biotechnology #biopharma #collaboration

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics